Activities
Naogen Pharma is a radiopharmaceutical company based in Nantes with the ambition to develop innovative products in cardiology and oncology using radionuclides produced by the high energy and high intensity cyclotron Arronax. Created in September 2016, at the end of the research project FUI (Fonds Unique Interministériel) Quanticardi, financed by the BPI (Public Investment Bank) and the Pays de Loire Region, the company has developed close to the site of Arronax with funds from private investors. Its expertise is based on the availability and mastery of all the necessary components for the development of radiopharmaceuticals, and in particular, for its first product, the possibility of performing Positron Emission Tomography (PET) imaging in patients with anomaly of myocardial infusion.
